Upon joining the trial, the participant will be randomly assigned to one of the study groups. This means that the participant will either receive the actual medication or a placebo, which is a substance with no active ingredients. The assignment is done randomly to ensure fairness and objectivity in the study results.

Participants with a prolonged dry cough will receive an inhaled medication called fluticasone propionate. This medication is administered using a device called an inhaler. The inhaler delivers the medication directly to the lungs through inhalation. The dosage is 125 micrograms per dose, and it is taken as prescribed by the study team.

Participants with a prolonged wet cough will receive an oral antibiotic called amoxicillin, clavulanic acid. This medication is taken by mouth in the form of a suspension. The dosage and frequency will be provided by the study team and must be followed as instructed.

Throughout the trial, participants will be monitored for any changes in their cough symptoms. The primary goal is to observe a significant reduction in cough, defined as either the complete cessation of coughing or at least a 75% reduction in symptom scores compared to the initial assessment over three consecutive days.

Participants may be required to attend follow-up visits or provide updates on their symptoms as part of the study’s monitoring process. These updates help the study team assess the effectiveness of the treatment.

At the end of the trial, participants will have a final assessment to evaluate the overall effectiveness of the treatment they received. This assessment will help determine if the medication was successful in reducing the symptoms of a prolonged cough.

Participants will be informed about the results of the trial and any further steps if necessary. The study team will provide guidance on any additional care or treatment that may be needed after the trial concludes.